14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $3.01 $5.59 Thursday, 2nd May 2024 NEXI stock ended at $3.12. This is 1.89% less than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 3.48% from a day low at $3.07 to a day high of $3.18.
90 days $3.01 $19.65
52 weeks $0.150 $28.69

Historical NexImmune, Inc. prices

Date Open High Low Close Volume
Feb 21, 2024 $8.22 $8.35 $7.76 $7.86 66 183
Feb 20, 2024 $8.00 $9.80 $7.78 $8.56 464 552
Feb 16, 2024 $8.19 $8.30 $7.69 $7.78 76 278
Feb 15, 2024 $8.78 $9.11 $8.19 $8.44 51 398
Feb 14, 2024 $9.02 $9.55 $8.88 $8.96 46 482
Feb 13, 2024 $9.74 $10.00 $8.85 $9.02 101 460
Feb 12, 2024 $8.71 $10.13 $8.55 $9.94 239 544
Feb 09, 2024 $9.02 $9.58 $8.70 $8.84 80 709
Feb 08, 2024 $9.10 $9.74 $8.51 $8.98 140 961
Feb 07, 2024 $10.46 $11.00 $8.52 $9.20 164 210
Feb 06, 2024 $10.49 $11.05 $10.49 $10.51 121 032
Feb 05, 2024 $11.77 $11.90 $10.68 $10.87 345 608
Feb 02, 2024 $14.01 $19.65 $12.50 $12.60 1 622 341
Feb 01, 2024 $13.75 $16.60 $12.70 $15.19 750 729
Jan 31, 2024 $19.19 $21.00 $11.20 $15.00 4 808 748
Jan 30, 2024 $8.50 $28.69 $8.36 $14.73 18 876 709
Jan 29, 2024 $5.84 $11.60 $5.59 $9.30 7 983 597
Jan 26, 2024 $5.12 $5.43 $5.10 $5.35 58 303
Jan 25, 2024 $5.19 $5.49 $4.84 $5.14 116 238
Jan 24, 2024 $5.00 $5.45 $5.00 $5.18 118 855
Jan 23, 2024 $5.51 $5.61 $5.00 $5.00 110 829
Jan 22, 2024 $6.39 $6.45 $5.31 $5.66 206 429
Jan 19, 2024 $8.25 $8.79 $7.00 $7.00 223 393
Jan 18, 2024 $8.86 $9.40 $8.32 $8.37 205 705
Jan 17, 2024 $9.61 $10.21 $8.32 $8.72 188 634
Click to get the best stock tips daily for free!

About NexImmune, Inc.

NexImmune. NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials f... NEXI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT